Rankings
▼
Calendar
RIGL Q4 2018 Earnings — Rigel Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
RIGL
Rigel Pharmaceuticals, Inc.
$517M
Q4 2018 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$38M
Gross Profit
$38M
99.5% margin
Operating Income
$3M
6.7% margin
Net Income
$3M
8.5% margin
EPS (Diluted)
$0.20
QoQ Revenue Growth
+678.2%
Cash Flow
Operating Cash Flow
$12M
Free Cash Flow
$12M
Stock-Based Comp.
$2M
Balance Sheet
Total Assets
$139M
Total Liabilities
$29M
Stockholders' Equity
$110M
Cash & Equivalents
$76M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$38M
$0
—
Gross Profit
$38M
-$12M
+425.8%
Operating Income
$3M
-$26M
+109.7%
Net Income
$3M
-$26M
+112.5%
← FY 2018
All Quarters
Q1 2019 →